HDAC9 and neuroblastoma: When entities were analysed separately, entinostat (class I HDAC inhibitor) and I-BET151 (BET bromodomain inhibitor) displayed entity-specific combination benefits with RA in MB and NB, respectively (Supplementary Figs. S5–6).